Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 7/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353387 | 0.81 | NPC1 (0.47) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL9628930 | 0.79 | MAPT (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL89000 | 0.77 | MEN1 (0.42) | NPC1MAPTCCNB2CDK1CCNB1 | |
| SCHEMBL3592048 | 0.75 | — | — | |
| SCHEMBL3604113 | 0.75 | AHR (0.31) | AHR | |
| SCHEMBL13545261 | 0.72 | AR (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3592399 | 0.72 | AHR (0.31) | AHR | |
| SCHEMBL11884804 | 0.72 | GSK3B (0.39) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL3598439 | 0.72 | AHR (0.34) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL3592393 | 0.72 | AHR (0.31) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018079628-A1 | PYRROLE DERIVATIVE WITH FUSED RING AND PHARMACEUTICAL USE THEREOF | 大日本住友製薬株式会社 | 2018-05-03 | — | — | WO | disclosed |
| WO-2017122495-A1 | CERAMIDE CONTENT INCREASING AGENTS | 国立大学法人富山大学 | 2017-07-20 | — | — | WO | disclosed |
| US-9012445-B2 | Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors | VANDERBILT UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013106795-A1 | SUBSTITUTED 4-(1H~PYRAZOL-4.YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8163773-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090233920-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-7049312-B1 | Benzothiazinone and benzoxazinone compounds | ABBOTT GMBH & CO. KG (DE) | 2006-05-23 | — | — | US | disclosed |
| EP-1181282-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000075139-A2 | BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | CHRM1, CHRM4, CHRM5 | AHR 1458/4885PDK2 3512/4885NPC1 1655/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | AHR 1704/4885PDK2 1211/4885NPC1 3663/4885 |
| US-20090233920-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | AHR 3149/4885PDK2 968/4885NPC1 2702/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | AHR 3178/4885PDK2 782/4885NPC1 2676/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | AHR 3514/4885PDK2 412/4885NPC1 2742/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | AHR 3785/4885PDK2 256/4885NPC1 1874/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | AHR 3660/4885PDK2 714/4885NPC1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.